Trial Profile

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 25 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INBRX 105 (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Carcinoma; Gastric cancer; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Oropharyngeal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms PDL1x41BB
Sponsors Inhibrx

23 Oct 2024 Status changed from active, no longer recruiting to discontinued.
25 Jul 2024 Status changed from recruiting to active, no longer recruiting.
06 Mar 2023 According to an Inhibrx media release, company expects to announce clinical data from these cohorts during the second half of 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com